BRPI0517003A - combinação de mycobacterium recombinante e um agente biologicamente ativo como vacina - Google Patents

combinação de mycobacterium recombinante e um agente biologicamente ativo como vacina

Info

Publication number
BRPI0517003A
BRPI0517003A BRPI0517003-6A BRPI0517003A BRPI0517003A BR PI0517003 A BRPI0517003 A BR PI0517003A BR PI0517003 A BRPI0517003 A BR PI0517003A BR PI0517003 A BRPI0517003 A BR PI0517003A
Authority
BR
Brazil
Prior art keywords
combination
biologically active
constituent
recombinant mycobacterium
active vaccine
Prior art date
Application number
BRPI0517003-6A
Other languages
English (en)
Inventor
Albrecht Laeufer
Bernd Eisele
Leander Grode
Original Assignee
Vakzine Projekt Man Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vakzine Projekt Man Gmbh filed Critical Vakzine Projekt Man Gmbh
Publication of BRPI0517003A publication Critical patent/BRPI0517003A/pt
Publication of BRPI0517003B1 publication Critical patent/BRPI0517003B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMBINAçãO DE MYCOBACTERIUM RECOMBINANTE E UM AGENTE BIOLOGICAMENTE ATIVO COMO VACINA. A presente invenção refere-se a uma combinação compreendendo um primeiro constituinte e um segundo constituinte, em que o primeiro constituinte é uma célula bacteriana que compreende pelo menos uma molécula de ácido nucléico recombinante que codifique um peptídio ou polipeptídio de escape fagolisossómico, e em que o segundo constituinte é um a- gente biologicamente ativo.
BRPI0517003-6A 2004-10-21 2005-10-16 Combinação compreendendo um primeiro constituinte e um segundo constituinte separado, composição farmacêutica e método de fabricação da mesma BRPI0517003B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04025096A EP1649869A1 (en) 2004-10-21 2004-10-21 Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
EP04025096.1 2004-10-21
PCT/EP2005/011127 WO2006045468A1 (en) 2004-10-21 2005-10-16 Combination of a recombinant mycobacterium and a biologically active agent as a vaccine

Publications (2)

Publication Number Publication Date
BRPI0517003A true BRPI0517003A (pt) 2008-09-30
BRPI0517003B1 BRPI0517003B1 (pt) 2021-10-13

Family

ID=35462399

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517003-6A BRPI0517003B1 (pt) 2004-10-21 2005-10-16 Combinação compreendendo um primeiro constituinte e um segundo constituinte separado, composição farmacêutica e método de fabricação da mesma

Country Status (17)

Country Link
US (1) US9078844B2 (pt)
EP (2) EP1649869A1 (pt)
JP (1) JP4836957B2 (pt)
KR (1) KR101300905B1 (pt)
CN (1) CN101048178B (pt)
AU (1) AU2005298976A1 (pt)
BR (1) BRPI0517003B1 (pt)
CA (1) CA2584321C (pt)
DK (1) DK1802340T3 (pt)
ES (1) ES2524921T3 (pt)
MX (1) MX2007004734A (pt)
PL (1) PL1802340T3 (pt)
PT (1) PT1802340E (pt)
RU (1) RU2495677C2 (pt)
SI (1) SI1802340T1 (pt)
UA (1) UA101140C2 (pt)
WO (1) WO2006045468A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1827504T3 (da) 2004-12-01 2011-08-29 Aeras Global Tb Vaccine Foundation Rekombinante BCG-stammer med forøget evne til at undslippe fra endosomet
CN101969976A (zh) 2008-01-11 2011-02-09 美国政府健康与人类服务部秘书处 针对分枝杆菌的多肽疫苗和接种策略
CN103118703A (zh) 2010-09-20 2013-05-22 疫苗项目管理有限公司 作为人用疫苗的重组分枝杆菌
ES2612777T3 (es) * 2010-12-21 2017-05-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Mycobacterium recombinante como una vacuna
EP2757155B1 (en) * 2011-09-13 2016-06-29 Japan BCG Laboratory Recombinant bcg vaccine
EP3090757A1 (en) * 2015-05-04 2016-11-09 Vakzine Projekt Management GmbH Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer
WO2020115161A1 (en) 2018-12-04 2020-06-11 Sabiotec Spin-Off Sl Immunostimulant for use against pathogens
US20230218684A1 (en) * 2020-03-30 2023-07-13 North Carolina State University Engineered bacteria for use in vaccine compositions
CN113499439B (zh) * 2021-07-20 2023-03-17 上海市肺科医院 结核菌UreC蛋白在制备抗结核分枝杆菌药物中的应用
JPWO2025234450A1 (pt) * 2024-05-08 2025-11-13

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169900A1 (en) * 1993-02-17 2005-08-04 Sloan Kettering Institute For Cancer Research Allogeneic vaccine and methods to synthesize same
EP0684831B1 (en) * 1993-02-17 2003-09-03 Sloan-Kettering Institute For Cancer Research Allogenic vaccine and method to synthesize same
DE19640817A1 (de) * 1996-10-02 1998-05-14 Hermann Prof Dr Bujard Rekombinantes Herstellungsverfahren für ein vollständiges Malaria-Antigen gp190/MSP 1
EP0902086A1 (en) * 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
DE19910044A1 (de) * 1999-03-08 2000-09-14 Bodo Plachter Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
AU3337300A (en) * 1999-03-15 2000-10-04 Agresearch Limited Treatment of asthma
DK1618128T3 (da) * 2003-04-23 2010-10-18 Max Planck Gesellschaft Tuberkulosevaccine med forbedret effektivitet
US7855268B2 (en) * 2006-06-01 2010-12-21 Allergan, Inc. Tolerogizing compositions comprising botulinum toxin type B peptides
US7670788B2 (en) * 2006-06-01 2010-03-02 Allergan, Inc. Determining and reducing immunoresistance to a Botulinum toxin therapy using Botulinum toxin B peptides

Also Published As

Publication number Publication date
WO2006045468A1 (en) 2006-05-04
KR20070068398A (ko) 2007-06-29
RU2007118675A (ru) 2008-11-27
US20080292656A1 (en) 2008-11-27
RU2495677C2 (ru) 2013-10-20
EP1802340B1 (en) 2014-09-03
JP4836957B2 (ja) 2011-12-14
JP2008517013A (ja) 2008-05-22
KR101300905B1 (ko) 2013-08-27
EP1802340A1 (en) 2007-07-04
SI1802340T1 (sl) 2015-01-30
ES2524921T3 (es) 2014-12-15
CA2584321A1 (en) 2006-05-04
HK1106929A1 (en) 2008-03-20
CN101048178B (zh) 2012-09-05
AU2005298976A1 (en) 2006-05-04
US9078844B2 (en) 2015-07-14
PT1802340E (pt) 2014-12-09
CN101048178A (zh) 2007-10-03
UA101140C2 (ru) 2013-03-11
CA2584321C (en) 2021-06-15
DK1802340T3 (en) 2014-12-01
PL1802340T3 (pl) 2015-03-31
MX2007004734A (es) 2007-07-13
EP1649869A1 (en) 2006-04-26
BRPI0517003B1 (pt) 2021-10-13

Similar Documents

Publication Publication Date Title
UA116080C2 (uk) Ліофілізована композиція терапевтичного пептидного антитіла
BRPI0513850A (pt) composição terapêutica com uma neurotoxina botulìnica
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
AR064642A1 (es) Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
UY31209A1 (es) Uso de homo y copolimeros para la estabilización de formulaciones de principios activos
NO20073808L (no) BCMA polypeptider og anvendelser derav
BR0207585A (pt) Método para melhorar o desempenho de crescimento de um animal, composição promotora do crescimento, e, construção para a liberação in vivo de uma quantidade eficaz de citocina
PL1767546T3 (pl) Hamujące angiogenezę białka chimeryczne i ich zastosowanie
BRPI0514835A (pt) variante de polipetìdeo de box de domìnio de ligação por alta afinidade de hmbg1 humano e/ou não humano ou de fragmento biologicamente ativo de box-a de hmgb1, molécula de ácido nucléico, uso, composição farmacêutica e dispositivo médico
PA8525201A1 (es) Tetrazolil-fenil acetamidas como activadores de la glucoquinasa
BR112013009157A2 (pt) polipeptídeos com atividade de permease
EA201190285A1 (ru) Иммуногенные композиции, имеющие низкую концентрацию хлорида натрия
BRPI0512878A (pt) formulações de suspensão de aerossol, com tg 227 ea ou tg 134 a como agente propulsor
MX2009005788A (es) Peptidos truncados de hormona paratiroidea con una conformacion ciclica.
DK1618128T3 (da) Tuberkulosevaccine med forbedret effektivitet
BRPI0612288A2 (pt) amilase modificada de pseudomonas saccharophilia
AR060827A1 (es) Metodo para bloquear la infeccion por flavivirus, moleculas y usos
AR082155A1 (es) Formulacion antiseptica y desinfectante que tiene contenido de yodo reducido
BRPI0407533A (pt) proteìnas de fusão e muteìnas do interferon alfa com propriedades melhoradas
BRPI0510259A (pt) formulação cosmética ou dermatológica transparente
PE20120400A1 (es) Contrucciones de casb7439
BR112023002926A2 (pt) Agentes terapêuticos inaláveis
UA101140C2 (ru) Комбинация рекомбинантной микобактерии и биологически активного агента как вакцины
BRPI0510016A (pt) vetor lentiviral recombinante para expressão de uma proteìna de flaviviridae e aplicações do mesmo como vacina
BRPI0715331B8 (pt) polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2150 DE 20/03/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/10/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.